HAYWARD, Calif., Feb. 5, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that Senior Vice President of Product Development Georgina Kilfoil has notified the company she will leave the company effective February 15, 2013 to pursue other opportunities.
"The Board and management of Anthera would like to thank Georgina for her years of dedicated service. Georgina's exemplary leadership and experience was instrumental in the advancement of Anthera's development programs. Her tireless efforts brought us to the starting line of our BRIGHT-SC phase 2 study for IgA Nephropathy and CHABLIS-SC phase 3 study for systemic lupus erythematosus, which we are excited to get underway this year," said Paul F. Truex, Anthera's President and Chief Executive Officer. "We wish Georgina all the best as she seeks to repeat her success in future endeavors."
Dr. Colin Hislop, Anthera's Senior Vice President and Chief Medical Officer, will continue to oversee all product development related activities for blisibimod.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering. Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those set forth in the Company's public filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. The Company disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., [email protected] or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc.